In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DMI BioSciences Inc.

Division of Ampio Pharmaceuticals Inc.

Latest From DMI BioSciences Inc.

Macaluso steps up as Ampio CEO takes compassionate leave

Don Wingerter, CEO of Ampio Pharmaceuticals, a company that discovers new uses for previously approved drugs, has been granted compassionate leave of indefinite length from all his duties to attend to the serious health problems afflicting his parents. Filling the breach is Michael Macaluso, current chair of the Ampio board of directors and lead investor in DMI BioSciences, predecessor company to Ampio.

Ampio Pharmaceuticals appoints new CFO

US-based Ampio Pharmaceuticals has named Mark McGregor chief financial officer and corporate secretary. Bruce Miller, who has served in these roles since April 2010, will join the team that will advance the commercialisation of Ampio's Phase III product candidate, Zertane, which was obtained through the acquisition of DMI BioSciences in 2010. Mr Miller had served as DMI's chief executive officer and/or president since 1992. Ampio is developing proprietary drugs for metabolic, eye and kidney diseases, inflammation, CNS disease and male sexual dysfunction.

Gynecology & Urology Orthopedics

Deals Shaping the Medical Industry (09/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Ampio finalises terms of DMI acquisition

Ampio Pharmaceuticals has finalised the terms of its previously announced acquisition of DMI BioSciences in a stock purchase.

Cardiovascular Gynecology & Urology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Parent & Subsidiaries
  • Ampio Pharmaceuticals Inc.
  • Senior Management
  • Contact Info
  • DMI BioSciences Inc.
    ,
Advertisement
Advertisement
UsernamePublicRestriction

Register